ArticleHealth economics review2025
Cost-utility analysis of eptinezumab for migraine prevention in Taiwan.
Article in Health economics review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cost-Utility Analysis of Calcitonin Gene-Related Peptide Monoclonal Antibodies for Patients with Episodic Migraine Headache in the USA.PharmacoEconomics · 2026Article
- Impact of migraine on work productivity of healthcare providers at Kasr Al-Ainy Hospital.BMC neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimMigraine is a neurological disorder prevalent in Taiwan, affecting millions of individuals and imposing a substantial burden on both quality of life and societal productivity. Calcitonin gene-related peptide inhibitors, such as eptinezumab, represent a major advancement in migraine prevention; however, their high cost and the lack of local economic evaluations warrant further study. This research aims to assess the cost-effectiveness of eptinezumab, compared with placebo, for migraine prevention in Taiwan.
methodsA Markov model with a six-month time horizon was developed to evaluate the cost-effectiveness of eptinezumab versus placebo. The analysis was conducted from a health payer’s perspective, incorporating clinical and economic inputs from clinical trials and the literature. Patients were categorized into six health states based on monthly migraine days. Outcomes were expressed as incremental costs per quality-adjusted life year (QALY) gained. Incremental cost-effectiveness ratios (ICERs) were estimated using a Monte Carlo simulation with 10,000 iterations, alongside deterministic and probabilistic sensitivity analyses to evaluate uncertainty. For interpretation, results were compared with Taiwan’s GDP per capita ($32,327 per QALY), and exploratory analyses also considered a threshold of three times GDP per capita ($96,981).
resultsOver six months, the total cost for patients receiving eptinezumab was $4,461, compared with $1,065 for placebo, with corresponding QALYs of 0.35 and 0.31, respectively. This yielded an ICER of $73,929 per QALY gained. Deterministic sensitivity analysis identified utility values for patients with varying migraine frequency as the most influential parameter, increasing the ICER to approximately $105,000 when varied, which may exceed the upper WTP threshold. Probabilistic sensitivity analysis showed that eptinezumab was cost-effective in 98% of iterations at the exploratory threshold of three times GDP per capita.
conclusionEptinezumab was likely cost-effective for migraine prevention in Taiwan, with utility values associated with migraine frequency identified as the key driver, highlighting the need for locally relevant quality-of-life data in future evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.